pf-04523655
Nucleic acidexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2007 (NCT00725686)
Timeline
Indications
Mechanism of action
- DNA damage-inducible transcript 4 proteinSupplementation
DDIT4 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- pf-04523655
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01445899 | Phase 2 | Feb 1, 2012 | Quark Pharmaceuticals |
| NCT00713518 | Phase 2 | Nov 1, 2009 | Pfizer, Quark Pharmaceuticals |
| NCT00701181 | Phase 2 | Jun 1, 2008 | Pfizer, Quark Pharmaceuticals |
| NCT00725686 | Phase 1 | Feb 1, 2007 | Pfizer, Quark Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Quark Pharmaceuticals | For profit | 4 | 4 | 2 | 2007 |
| Pfizer | For profit | 3 | 0 | 2 | 2007 |
2 organizations
Page 1 / 1